X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (427) 427
prostate cancer (385) 385
humans (346) 346
male (305) 305
oncology (282) 282
metastasis (263) 263
metastatic castration-resistant prostate cancer (238) 238
chemotherapy (211) 211
docetaxel (190) 190
cancer (178) 178
survival (167) 167
prostatic neoplasms, castration-resistant - drug therapy (163) 163
abiraterone acetate (154) 154
aged (152) 152
urology & nephrology (152) 152
enzalutamide (138) 138
middle aged (134) 134
care and treatment (128) 128
prostatic neoplasms, castration-resistant - pathology (121) 121
double-blind (115) 115
treatment outcome (115) 115
abiraterone (106) 106
prednisone (101) 101
men (100) 100
increased survival (97) 97
metastases (95) 95
antineoplastic agents - therapeutic use (93) 93
prostate (93) 93
castration (91) 91
aged, 80 and over (90) 90
patients (90) 90
metastatic prostate cancer (87) 87
mitoxantrone (84) 84
urology (80) 80
immunotherapy (79) 79
neoplasm metastasis (79) 79
medicine & public health (78) 78
analysis (73) 73
research (73) 73
prognosis (71) 71
cabazitaxel (69) 69
therapy (69) 69
cancer therapies (68) 68
clinical trials (67) 67
androgens (66) 66
metastatic (65) 65
survival analysis (65) 65
mitoxantrone plus prednisone (62) 62
retrospective studies (62) 62
disease-free survival (60) 60
taxoids - therapeutic use (60) 60
antineoplastic combined chemotherapy protocols - therapeutic use (58) 58
prostatic neoplasms - drug therapy (55) 55
article (53) 53
prostatic neoplasms, castration-resistant - mortality (53) 53
drug therapy (52) 52
development and progression (50) 50
prostate-specific antigen - blood (50) 50
review (50) 50
pharmacology & pharmacy (49) 49
prostatic neoplasms - pathology (49) 49
antigens (46) 46
disease progression (46) 46
plus prednisone (45) 45
sipuleucel-t (45) 45
androgen receptor (44) 44
hematology, oncology and palliative medicine (44) 44
phenylthiohydantoin - analogs & derivatives (44) 44
taxoids - administration & dosage (44) 44
bone neoplasms - secondary (43) 43
bone metastases (42) 42
health aspects (41) 41
resistant prostate-cancer (41) 41
prostate-specific antigen (40) 40
androgen antagonists - therapeutic use (39) 39
kaplan-meier estimate (38) 38
prostatic neoplasms - therapy (38) 38
tumors (38) 38
antitumor-activity (37) 37
quality of life (37) 37
adult (36) 36
androgen-deprivation therapy (36) 36
medical prognosis (36) 36
prostatic neoplasms, castration-resistant - blood (36) 36
trial (36) 36
medical research (35) 35
metastatic castration‐resistant prostate cancer (35) 35
open-label (35) 35
animals (34) 34
phenylthiohydantoin - therapeutic use (34) 34
antineoplastic agents - adverse effects (33) 33
expression (33) 33
safety (33) 33
survival rate (33) 33
clinical-trials (32) 32
corticosteroids (32) 32
pain (32) 32
antineoplastic agents (31) 31
androgen deprivation therapy (30) 30
metastatic breast-cancer (30) 30
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Clinical Medicine Insights: Oncology, ISSN 1179-5549, 03/2014, Volume 2014, Issue 8, pp. 29 - 36
Introduction This study aims to make an indirect comparison between enzalutamide and abiraterone acetate for mCRPC post-docetaxel. Methods A search for... 
mCRPC | Enzalutamide | Metastatic castration-resistant prostate cancer | Abiraterone acetate | Post-docetaxel | Antimitotic agents | Care and treatment | Metastasis | Antineoplastic agents | Prostate cancer | Analysis
Journal Article
Prostate Cancer and Prostatic Diseases, ISSN 1365-7852, 2019, Volume 23, Issue 1, pp. 66 - 73
Multiple androgens drive prostate cancer progression and higher pre-treatment levels of androgens, even within the castrate range, have been previously shown... 
Evaluation | Mass spectroscopy | Liquid chromatography | Prednisone | Survival | Bevacizumab | Metastases | Impact analysis | Testosterone | Androgens | Chemotherapy | Statistical models | Castration | Medical prognosis | Microtubules | Health hazards | Pretreatment | Hazard assessment | Androstenedione | Prostate cancer | Mass spectrometry | Prostate | Cancer
Journal Article
Journal Article
Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, ISSN 1098-3015, 10/2017, Volume 20, Issue 9, p. A446
OBJECTIVES: This study aimed to determine the hospital resource use in metastatic castration resistant prostate cancer (CRPC) in national university hospitals... 
Radiation | Population studies | Biochemistry | Metastasis | Scintigraphy | Medical diagnosis | Blood | Metastases | Databases | Castration | Computed tomography | Imaging | Opioids | Bones | Diagnosis | Deprivation | Medical procedures | Metastatic cancer | Hospitalization | Radiation therapy | Patient admissions | Patients | Bone cancer | Androgens | Hospitals | Lungs | Inpatient care | Bone imaging | Prostate cancer | Prostate
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2011, Volume 22, Issue 11, pp. 2476 - 2481
Journal Article
Cancer, ISSN 0008-543X, 05/2017, Volume 123, Issue 9, pp. 1528 - 1535
BACKGROUND Skeletal‐related events (SREs) are common complications of bone metastatic castration‐resistant prostate cancer (mCRPC). To the authors' knowledge,... 
bone metastases | bone pain | prostate cancer | metastatic castration‐resistant prostate cancer (mCRPC) | skeletal‐related event (SRE) | metastatic castration-resistant prostate cancer (mCRPC) | skeletal-related event (SRE) | SURVIVAL | MORTALITY | PROGNOSTIC-FACTORS | DENOSUMAB | ZOLEDRONIC ACID | BREAST-CANCER | TRIAL | PAIN | ONCOLOGY | MEN | COMPLICATIONS | Multivariate Analysis | Bone Neoplasms - therapy | Follow-Up Studies | Pain - epidemiology | Fractures, Spontaneous - epidemiology | Radiotherapy - utilization | Humans | Bone Neoplasms - secondary | Bone Neoplasms - epidemiology | Male | Prostatic Neoplasms, Castration-Resistant - pathology | Neoplasm Grading | Aged, 80 and over | Kallikreins - blood | Retrospective Studies | Bone Neoplasms - blood | Prostatic Neoplasms, Castration-Resistant - epidemiology | Prostatic Neoplasms, Castration-Resistant - blood | Risk Factors | Proportional Hazards Models | Spinal Cord Compression - epidemiology | Bone and Bones - surgery | Prostate-Specific Antigen - blood | Orthopedic Procedures - utilization | Aged | Cancer patients | Diagnosis | Health aspects | Prostate cancer | Identification methods | Complications | Prostate-specific antigen | Health risks | Clinical trials | Medical records | Risk reduction | Metastasis | Radiation therapy | Health care facilities | Risk analysis | Patients | Risk factors | Metastases | Bone cancer | Pain | Castration | Biopsy | Men | Mathematical models | Prostate | Cancer | skeletal related event (SRE)
Journal Article
Neoplasia, ISSN 1476-5586, 08/2019, Volume 21, Issue 8, pp. 802 - 809
While circulating tumor cell (CTC)–based detection of AR-V7 has been demonstrated to predict patient response to second-generation androgen receptor therapies,... 
POLYMERASE-CHAIN-REACTION | ANDROGEN-RECEPTOR GENE | AR-V7 | ONCOLOGY | INCREASED SURVIVAL | EXPRESSION | ANTIGEN
Journal Article
The Prostate, ISSN 0270-4137, 07/2018, Volume 78, Issue 10, pp. 766 - 772
Journal Article
Journal of the Canadian Urological Association, ISSN 1911-6470, 04/2016, Volume 10, Issue 3-4, pp. 111 - 112
Journal Article
Pathology & Oncology Research, ISSN 1219-4956, 10/2017, Volume 23, Issue 4, pp. 777 - 783
Journal Article